Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
In acute myeloid leukemia (AML), several signaling pathways such as the phosphatidylinositol-3-kinase/AKT and the mammalian target of rapamycin (PI3K/AKT/mTOR) pathway are deregulated and constitutively activated as a consequence of genetic and cytogenetic abnormalities. We tested the effectiveness...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2015
|
| In: |
Leukemia
Year: 2015, Jahrgang: 29, Heft: 4, Pages: 828-838 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2014.305 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2014.305 Verlag, Volltext: https://www.nature.com/leu/journal/v29/n4/full/leu2014305a.html 
|
| Verfasserangaben: | N. Sandhöfer, K.H. Metzeler, M. Rothenberg, T. Herold, S. Tiedt, V. Groiß, M. Carlet, G. Walter, T. Hinrichsen, O. Wachter, M. Grunert, S. Schneider, M. Subklewe, A. Dufour, S. Fröhling, H.-G. Klein, W. Hiddemann, I. Jeremias and K. Spiekermann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1561187003 | ||
| 003 | DE-627 | ||
| 005 | 20220813202634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170725s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2014.305 |2 doi | |
| 035 | |a (DE-627)1561187003 | ||
| 035 | |a (DE-576)491187009 | ||
| 035 | |a (DE-599)BSZ491187009 | ||
| 035 | |a (OCoLC)1340977700 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sandhöfer, Nadine |e VerfasserIn |0 (DE-588)1137237090 |0 (DE-627)894235818 |0 (DE-576)491186924 |4 aut | |
| 245 | 1 | 0 | |a Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia |c N. Sandhöfer, K.H. Metzeler, M. Rothenberg, T. Herold, S. Tiedt, V. Groiß, M. Carlet, G. Walter, T. Hinrichsen, O. Wachter, M. Grunert, S. Schneider, M. Subklewe, A. Dufour, S. Fröhling, H.-G. Klein, W. Hiddemann, I. Jeremias and K. Spiekermann |
| 264 | 1 | |c 2015 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a published online 21 November 2014 | ||
| 500 | |a Gesehen am 25.07.2017 | ||
| 520 | |a In acute myeloid leukemia (AML), several signaling pathways such as the phosphatidylinositol-3-kinase/AKT and the mammalian target of rapamycin (PI3K/AKT/mTOR) pathway are deregulated and constitutively activated as a consequence of genetic and cytogenetic abnormalities. We tested the effectiveness of PI3K/AKT/mTOR-targeting therapies and tried to identify alterations that associate with treatment sensitivity. By analyzing primary samples and cell lines, we observed a wide range of cytotoxic activity for inhibition of AKT (MK-2206), mTORC1 (rapamycin) and PI3K/mTORC1/2 (BEZ-235) with a high sensitivity of cells carrying an MLL rearrangement. In vivo PI3K/mTOR inhibition delayed tumor progression, reduced tumor load and prolonged survival in an MLL-AF9+/FLT3-ITD+ xenograft mouse model. By performing targeted amplicon sequencing in 38 MLL-AF9+ and 125 cytogenetically normal AML patient samples, we found a high additional mutation rate for genes involved in growth factor signaling in 79% of all MLL-AF9+ samples, which could lead to a possible benefit of this cohort. PI3K/mTOR inhibition for 24 h led to the cross-activation of the ERK pathway. Further in vitro studies combining PI3K/mTOR and ERK pathway inhibition revealed highly synergistic effects in apoptosis assays. Our data implicate a possible therapeutic benefit of PI3K/mTOR inhibition in the MLL-mutated subgroup. Inhibiting rescue pathways could improve the therapeutic efficacy of PI3K-targeted therapies in AML. | ||
| 700 | 1 | |a Walter, Gina J. |e VerfasserIn |0 (DE-588)1137237392 |0 (DE-627)894236083 |0 (DE-576)491186819 |4 aut | |
| 700 | 1 | |a Fröhling, Stefan |d 1969- |e VerfasserIn |0 (DE-588)120890046 |0 (DE-627)080950302 |0 (DE-576)188733930 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 29(2015), 4, Seite 828-838 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia |
| 773 | 1 | 8 | |g volume:29 |g year:2015 |g number:4 |g pages:828-838 |g extent:11 |a Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2014.305 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/leu/journal/v29/n4/full/leu2014305a.html |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170725 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 120890046 |a Fröhling, Stefan |m 120890046:Fröhling, Stefan |d 50000 |e 50000PF120890046 |k 0/50000/ |p 15 | ||
| 998 | |g 1137237392 |a Walter, Gina J. |m 1137237392:Walter, Gina J. |d 50000 |e 50000PW1137237392 |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1561187003 |e 2975153406 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1561187003","person":[{"display":"Sandhöfer, Nadine","given":"Nadine","role":"aut","family":"Sandhöfer"},{"family":"Walter","role":"aut","display":"Walter, Gina J.","given":"Gina J."},{"given":"Stefan","display":"Fröhling, Stefan","family":"Fröhling","role":"aut"}],"note":["published online 21 November 2014","Gesehen am 25.07.2017"],"name":{"displayForm":["N. Sandhöfer, K.H. Metzeler, M. Rothenberg, T. Herold, S. Tiedt, V. Groiß, M. Carlet, G. Walter, T. Hinrichsen, O. Wachter, M. Grunert, S. Schneider, M. Subklewe, A. Dufour, S. Fröhling, H.-G. Klein, W. Hiddemann, I. Jeremias and K. Spiekermann"]},"language":["eng"],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemiaLeukemia","language":["eng"],"part":{"year":"2015","volume":"29","text":"29(2015), 4, Seite 828-838","issue":"4","extent":"11","pages":"828-838"},"note":["Gesehen am 15.03.04"],"pubHistory":["Nachgewiesen 11.1997 -"],"title":[{"title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1476-5551"],"eki":["32046699X"],"zdb":["2008023-2"]},"origin":[{"dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedKey":"1997"}],"recId":"32046699X"}],"origin":[{"dateIssuedDisp":"2015","dateIssuedKey":"2015"}],"title":[{"title_sort":"Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia","title":"Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1561187003"],"doi":["10.1038/leu.2014.305"]},"physDesc":[{"extent":"11 S."}]} | ||
| SRT | |a SANDHOEFERDUALPI3KMT2015 | ||